Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response

Name: Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response
Brand: Springer Nature
SKU: 9781603270885
Availability: InStock

Best Price (Coupon Required):
Buy Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response for $152.10 at @ Link.springer.com when you apply the 10% OFF coupon at checkout.
Click “Get Coupon & Buy” to copy the code and unlock the deal.

Set a price drop alert to never miss an offer.

1 Offer Price Range: $169.00 - $169.00

BEST PRICE

Single Product Purchase

$152.10

@ Link.springer.com with extra coupon

Price Comparison

Seller	Contact Seller	List Price	On Sale	Shipping	Best Promo	Final Price	Volume Discount	Financing	Availability	Seller's Page
BEST PRICE 1 Product Purchase @ Link.springer.com		$169.00	$169.00		10% OFF This deals requires coupon	$152.10		See Site	In stock	Visit Store

Product Details

Brand

Springer Nature

Manufacturer

N/A

Part Number

GTIN

9781603270885

Condition

New

Product Description

Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response provides the most comprehensive body of knowledge available on the role of genetic and genomic variation in the individualization of drug therapies in cancer patients. As a consequence of the intrinsic chromosomal and genetic instability of the tumor genome, it is generally believed that tailoring of chemotherapy in cancer - tients might be achieved by molecular analysis of patient tumor DNA. In addition, to reduce the toxicity risk of patients, the tumor DNA information should be in- grated with the available data on polymorphic drug-metabolizing enzyme and tra- porter genes mediating the exposure of patients to active drugs and/or their active metabolites. The chapters of this book clearly show how DNA information from both the host (germline) and the tumor should be taken into account for rational selection of drug therapies in cancer patients, an aspect that received little attention, despite its importance. The availability of new molecular approaches to the selection of drug therapy is an emerging need, because the traditional approach based on the evaluation of patient and tumor characteristics is clearly far from optimal. Many treated patients do not experience signi?cant bene?ts from the treatment, while they often experience moderate to severe toxicities. In addition, the development and clinical use of novel molecularly targeted agents (alone or in combination with classical cytotoxic therapy) requires the und- standing of the molecular features of the tumors and the identi?cation of tumor markers of response.

Available Colors

N/A

Available Sizes

N/A

Reviews

0 reviews

5 stars

4 stars

3 stars

2 stars

1 star

Questions & Answers

Similar Products

Drones and US Grand Strategy in the Contemporary World

$99.00

Bunny Reads Back: The Bear Went Over the Mountain

$5.24

Active Lighting and Its Application for Computer Vision

$199.99

Industrial Cleaning Technology

$219.99

The Life-Changing Magic of Not Giving a F*ck- How to Stop Spending Time You Don't Have with People You Don't Like Doing Things You Don't Want to Do by

$22.99